

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>HAEMONETICS CORP</u> <hr/> (Last) (First) (Middle) <u>400 WOOD ROAD</u> <hr/> (Street) <u>BRAINTREE MA 02184</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>GLOBAL MED TECHNOLOGIES INC [GLOB]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>03/25/2010</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	03/25/2010		j ⁽¹⁾⁽²⁾		103,700	A	\$1.22	31,532,430 ⁽³⁾	I	See Footnote ⁽⁴⁾
Common Stock	03/26/2010		j ⁽¹⁾⁽²⁾		827,303	A	\$1.22	32,359,733 ⁽³⁾	I	See Footnote ⁽⁴⁾
Common Stock	03/29/2010		j ⁽¹⁾⁽²⁾		1,590,800	A	\$1.22	33,950,533 ⁽³⁾	I	See Footnote ⁽⁴⁾
Common Stock	03/30/2010		j ⁽¹⁾⁽²⁾		41,000	A	\$1.22	33,991,533 ⁽³⁾	I	See Footnote ⁽⁴⁾
Common Stock	03/31/2010		j ⁽¹⁾⁽²⁾		406,519	A	\$1.22	34,398,052 ⁽³⁾	I	See Footnote ⁽⁴⁾
Common Stock	04/01/2010		j ⁽¹⁾⁽⁵⁾		1,036,776	A	\$1.22	35,434,828 ⁽³⁾	I	See Footnote ⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
HAEMONETICS CORP

 (Last) (First) (Middle)
400 WOOD ROAD

 (Street)
BRAINTREE MA 02184

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Atlas Acquisition Corp.

 (Last) (First) (Middle)
C/O HAEMONETICS CORPORATION
400 WOOD ROAD

(Street)	BRAINTREE	MA	02184
(City)		(State)	(Zip)

Explanation of Responses:

1. In accordance with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 31, 2010, by and among Haemonetics Corporation, a Massachusetts corporation ("Haemonetics"), Atlas Acquisition Corp., a Colorado corporation and a direct wholly-owned subsidiary of Haemonetics, and Global Med Technologies, Inc., a Colorado corporation ("Global Med"), Atlas Acquisition Corp. commenced a cash tender offer (the "Offer") to purchase all outstanding shares of Global Med Common Stock, \$0.01 par value per share (the "Common Shares"), and Series A Convertible Preferred Stock, \$0.01 par value per share ("Preferred Shares"), subject to the terms and conditions set forth in the Offer to Purchase, dated February 19, 2010, as amended (the "Offer to Purchase"), included as an exhibit to the Tender Offer Statement on Schedule TO filed by Haemonetics and Atlas Acquisition Corp. with the Securities and Exchange Commission on February 19, 2010.
2. The reported Common Shares were purchased during the subsequent offering period contemplated by the Merger Agreement and the Offer to Purchase.
3. Excludes 5,500,000 Common Shares issuable upon conversion of 3,960 Preferred Shares of the Issuer, which Preferred Shares are subject to "blocker" provisions prohibiting the holder from converting the Preferred Shares to the extent that such conversion would result in the holder becoming the beneficial owner of more than 9.99% of the outstanding Common Shares.
4. The reported securities are owned indirectly by Haemonetics and directly by Atlas Acquisition Corp.
5. The reported Common Shares were purchased upon exercise of the "top-up option" contemplated by the Merger Agreement and the Offer to Purchase.

Remarks:

This report is filed jointly by Haemonetics Corporation and Atlas Acquisition Corp.

HAEMONETICS
CORPORATION /s/
Christopher J. Lindop, its Chief 04/01/2010
Financial Officer

ATLAS ACQUISITION
CORP. /s/ Christopher J. 04/01/2010
Lindop, its President

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.